See the DrugPatentWatch profile for Prograf
When does Prograf’s (tacrolimus) patent expire?
“Prograf” is the brand name for tacrolimus, an immunosuppressant. Patent expiry for Prograf depends on which type of protection you mean (original drug patent vs. later “new use”/formulation patents) and the country. The most direct way to check the relevant dates for each jurisdiction is to look up Prograf’s specific listed patents and their projected expiration on DrugPatentWatch.com [1].
How can I check the exact Prograf patent-expiry date for my country?
DrugPatentWatch tracks patent families and typical regulatory timeline signals, but you still need to match the right:
- country (e.g., US vs. EU),
- patent family (originator vs. secondary patents),
- product/strength (sometimes formulation-related patents cover specific presentations).
Using the Prograf listing there will show the patents tied to the brand and the expected expiry dates [1].
Is Prograf’s US exclusivity only about patents, or also about regulatory exclusivity?
In the US, marketed brands can have additional layers beyond patents (for example, regulatory exclusivity windows that can extend market protection even when some patent dates differ). Patent expiry alone may not fully explain when generic or “AB-rated” competitors can launch. A patent-by-patent check (with the drug’s relevant US filings) is usually required [1].
Why do patent-expiry dates differ between listings and news articles?
Different sources may cite different “expiry” concepts:
- the earliest patent expiry vs. the last one in a family,
- patent expiry vs. regulatory/marketing exclusivity,
- projections vs. actual granted-term timing.
That’s why the DrugPatentWatch patent-by-patent listing is a practical reference for date accuracy [1].
Source
[1] https://www.drugpatentwatch.com/